Organisation paid for research Program year 2025 Source: CMS Open Payments

PNS Clinical Research LLC

Neither a doctor nor a teaching hospital

Research payments

$558,870

96 payments

Through program year 2025, PNS Clinical Research LLC is reported as receiving $558,870 in research payments, across 96 payments.

By program year

2 rows
Year Kind Amount Payments
2025 Research $294,516 60
2024 Research $264,353 36

Breakdown

Who paid Research payments · program years 2024–2025
  1. Boehringer Ingelheim Pharmaceuticals, Inc. $255,027 10 payments
  2. Janssen Research & Development, LLC $144,952 14 payments
  3. AbbVie, Inc. $59,914 16 payments
  4. ACADIA Pharmaceuticals Inc $57,978 15 payments
  5. ITI, Inc. $26,364 8 payments
  6. Indivior Inc. $14,635 33 payments
Studies the money was for Research payments · program years 2024–2025
  1. Connex-2 $116,223 2 payments
  2. A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate-to-severe Anhedonia an $89,377 11 payments
  3. An open label, single arm, extension trial to examine long-term safety of BI 425809 once daily in patients with schizophrenia who have completed previous BI 425809 Phase III trials.(CONNEX-X) $51,535 4 payments
  4. A phase III trial to examine the efficacy and safety of Iclepertin once daily over 26 week treatment period in patients with schizophrenia (CONNEX-2) $46,558 3 payments
  5. Connex-X $40,711 1 payment
  6. A 52-week, Phase 2, Open-label Trial to Evaluate the Long-term Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia $37,415 6 payments
  7. A Randomized, Double-blind, Multicenter, Placebo-controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-89495120 as Monotherapy in Adult Participants with Major Depressive Disorder (MDD) $36,975 2 payments
  8. Acp-204-006 $34,619 12 payments
  9. A Randomized, Double-blind, Multicenter, Placebo-controlled Study of Adjunctive Aticaprant Plus an Antidepressant for Relapse Prevention in Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia VENTURA-5 $18,600 1 payment
  10. A Phase IV Longitudinal Study of SUBLOCADE (SUBUTEX Prolonged Release) Clinical Outcomes in Adults With Opioid Use Disorder (Opioid Dependence) $14,635 33 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record